Acurx Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: ACXP · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1736243
Sentiment: neutral
Topics: proxy statement, annual meeting, virtual meeting, board of directors, independent auditor
TL;DR
<b>Acurx Pharmaceuticals will hold its 2024 annual meeting virtually on June 17, 2024, to elect directors and ratify auditors.</b>
AI Summary
Acurx Pharmaceuticals, Inc. (ACXP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Acurx Pharmaceuticals, Inc. will hold its 2024 annual meeting of stockholders virtually via live audio webcast on June 17, 2024, at 10:00 a.m. EST. Stockholders can attend, vote, and submit questions online at www.virtualshareholdermeeting.com/ACXP2024. Three Class III directors will be elected to the board of directors at the meeting. Stockholders will be asked to ratify the appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The company is utilizing the SEC's e-proxy rules to deliver proxy materials electronically to conserve resources.
Why It Matters
For investors and stakeholders tracking Acurx Pharmaceuticals, Inc., this filing contains several important signals. The virtual format aims to increase stockholder participation and reduce costs and environmental impact compared to an in-person meeting. The meeting will cover director elections and the ratification of the independent auditor, CohnReznick LLP, for fiscal year 2024.
Risk Assessment
Risk Level: low — Acurx Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting with no significant new financial or operational disclosures, indicating low immediate risk.
Analyst Insight
Stockholders should review the proxy materials to make informed voting decisions on director nominees and auditor ratification.
Key Numbers
- 3 — Directors to be elected (Number of Class III directors to be elected to the board)
- 10:00 a.m. EST — Meeting Time (Time of the virtual annual meeting)
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement
- CohnReznick LLP (company) — Proposed independent registered public accounting firm
- June 17, 2024 (date) — Date of the annual meeting
- 2024 (date) — Year of the annual meeting and fiscal year end
- December 31, 2024 (date) — Fiscal year end for which auditor is being ratified
- 20240429 (date) — Filing date
FAQ
When did Acurx Pharmaceuticals, Inc. file this DEF 14A?
Acurx Pharmaceuticals, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Acurx Pharmaceuticals, Inc. (ACXP).
Where can I read the original DEF 14A filing from Acurx Pharmaceuticals, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Acurx Pharmaceuticals, Inc..
What are the key takeaways from Acurx Pharmaceuticals, Inc.'s DEF 14A?
Acurx Pharmaceuticals, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: Acurx Pharmaceuticals, Inc. will hold its 2024 annual meeting of stockholders virtually via live audio webcast on June 17, 2024, at 10:00 a.m. EST.. Stockholders can attend, vote, and submit questions online at www.virtualshareholdermeeting.com/ACXP2024.. Three Class III directors will be elected to the board of directors at the meeting..
Is Acurx Pharmaceuticals, Inc. a risky investment based on this filing?
Based on this DEF 14A, Acurx Pharmaceuticals, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting with no significant new financial or operational disclosures, indicating low immediate risk.
What should investors do after reading Acurx Pharmaceuticals, Inc.'s DEF 14A?
Stockholders should review the proxy materials to make informed voting decisions on director nominees and auditor ratification. The overall sentiment from this filing is neutral.
Risk Factors
- Compliance with SEC Proxy Rules [low — regulatory]: The company must comply with all SEC rules and regulations regarding the filing and distribution of proxy materials.
- Virtual Meeting Technology [low — operational]: Reliance on virtual meeting technology may present technical challenges or limit accessibility for some stockholders.
Key Dates
- 2024-06-17: 2024 Annual Meeting of Stockholders — Key date for stockholder voting and participation.
- 2024-04-29: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Glossary
- DEF 14A
- Definitive Proxy Statement (This filing type indicates the company is providing its final proxy materials to shareholders for voting.)
- Proxy Statement
- A document filed with the SEC that contains information that a company must provide to shareholders before their annual meeting, or before they vote on certain matters. (Essential document for shareholders to understand the issues being voted on, such as director elections and auditor ratification.)
- Class III Directors
- Directors elected for a specific term, typically serving three-year staggered terms. (Indicates the specific group of directors up for election at this annual meeting.)
Filing Stats: 4,865 words · 19 min read · ~16 pages · Grade level 11.2 · Accepted 2024-04-29 16:07:24
Key Financial Figures
- $15,000 — ces, we will pay a fee of approximately $15,000 plus expenses. What Constitutes a Quo
Filing Documents
- tm242861-2_def14a.htm (DEF 14A) — 459KB
- sg_davidplusi-bw.jpg (GRAPHIC) — 7KB
- px_24acurxproxy01pg01-bw.jpg (GRAPHIC) — 197KB
- px_24acurxproxy01pg02-bw.jpg (GRAPHIC) — 207KB
- 0001104659-24-054014.txt ( ) — 966KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 6 MANAGEMENT AND CORPORATE GOVERNANCE 7 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 15 EQUITY COMPENSATION PLAN INFORMATION 20 REPORT OF AUDIT COMMITTEE 21 DELINQUENT SECTION 16(A) REPORTS 22 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 23 PROPOSAL NO. 1—ELECTION OF DIRECTORS 25 PROPOSAL NO. 2—RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 26 CODE OF CONDUCT AND ETHICS 28 OTHER MATTERS 28 STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR 28 i TABLE OF CONTENTS Acurx Pharmaceuticals, Inc. 259 Liberty Avenue PROXY STATEMENT FOR THE ACURX PHARMACEUTICALS, INC. ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 17, 2024 This proxy statement, along with the accompanying notice of 2024 annual meeting of stockholders, contains information about the 2024 annual meeting of stockholders of Acurx Pharmaceuticals, Inc., including any adjournments or postponements of the annual meeting. We are holding the annual meeting at 10:00 a.m. EST, on Monday, June 17, 2024. This year's meeting will be a virtual meeting via live webcast on the Internet. You will be able to attend our annual meeting, vote and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/ACXP2024. You will not be able to attend the annual meeting in person. In this proxy statement, we refer to Acurx Pharmaceuticals, Inc. as "Acurx," "the Company," "we" and "us." This proxy statement relates to the solicitation of proxies by our board of directors for use at the annual meeting. On or about May 2, 2024, we intend to begin sending to our stockholders the Important Notice Regarding the Availability of Proxy Materials containing instructions on how to access our proxy statement for our 2024 annual meeting of stockholders and our 2023 annual report to stockholders. TABLE OF CONTENTS IMPORTANT NO
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following t